研究人员发现肺癌免疫反应中存在基于性别的差异,在女性中流行CXCL13,在女性肿瘤中则使用高T细胞活化。 Researchers found sex-based differences in lung cancer immune responses, with CXCL13 prevalent in females and higher T-cell activation in female tumors.

圣路易斯大学医学院的研究人员发现,肺癌病人的T细胞免疫反应有明显的性别差异。 Researchers at Saint Louis University School of Medicine have found significant sex-based differences in T-cell immune responses in lung cancer patients. 他们的研究表明,蛋白质CXCL13表明免疫疗法反应在女性中更为普遍。 Their study revealed that the protein CXCL13, which indicates immunotherapy response, is more prevalent in females. 雌性肿瘤中的T细胞的活化水平较高,而雄性肿瘤的免疫抑制型T细胞则较多。 T-cells in female tumors showed high activation levels, while male tumors had more immune-suppressive T-cells. 这些调查结果表明,有可能根据性别进行量身定做的癌症治疗。 These findings suggest the potential for tailored cancer treatments based on sex.